Atopic Dermatitis

Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.

The FDA has added efficacy and safety data for patients ages 12 years and older with uncontrolled moderate-to-severe atopic dermatitis with hand and/or foot involvement.

The pooled analyses from Arcutis’ INTEGUMENT-1 and INTEGUMENT-2 studies were presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Study findings suggest that Lavandula species, with their historical use in folk medicine, could emerge as valuable additions to AD treatment regimens. However, it's crucial to note that the efficacy of these oils is concentration-dependent.

Test your knowledge and explore a recent study on the relationship between alcohol consumption and skin diseases, including atopic dermatitis.

The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.

Expert dermatologists discuss the use of nonsteroidal treatment formulations for the treatment of AD, focusing on a topical treatment, tapinarof cream, 1%.

A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in atopic dermatitis this year.

An expert in the management of skin conditions highlights the case of a 45-year-old female with severe pruritus, erythematous rash, and lichenification across multiple body areas, worsened by recent work-related stress from a promotion. Dr. Lio offers insights into managing such patients and shares practical tips for a streamlined prescription process.

Peter Lio, MD, presents the case of a 56-year-old female with a history of severe atopic dermatitis and very dry skin. Dr. Lio discusses the significance of accurate disease diagnosis, tools for assessing severity, and the array of treatment options available for this patient. He emphasizes the importance of shared decision-making in managing the condition.

The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options. She also reviews the significance of patient assistance programs in facilitating patient access to and affordability of pharmaceutical therapies.

Tina Bhutani-Jacques, MD, presents the case of a 28-year old male with atopic dermatits, wherein the patient attributes his flares to his housing conditions. She discusses the role of patient counseling, shared decision making, and sustained disease control in the management of patients suffering from this condition.

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies. Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. Additionally, the discussion explores strategies for communicating treatment mechanisms to patients and fostering collaborative engagement in the treatment selection process.

TJ Chao, MPAS, PA-C, examines the case of an 18-year-old female with persistent AD, wherein the patient attributes her flares to her housing conditions. He discusses her treatment plan and addresses the challenges posed by red face syndrome induced by dupilumab, while commenting on how the panel managed patient expectations, treatment preferences, and sustained disease control.

Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.